Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced participation by CEO Christopher Posner in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 1:30 p.m. ET. Attendees can access the event via the company’s website under 'Events & Presentations,' with an archived recording available for 30 days post-event. Cara is recognized for its FDA-approved KORSUVA™ (difelikefalin) injection, the first treatment for moderate-to-severe pruritus in chronic kidney disease patients undergoing hemodialysis. The company is advancing additional formulations and ongoing clinical trials.

STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will participate in a fireside chat at the 21^st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 1:30 p.m. ET.

A webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

When is Cara Therapeutics' fireside chat at the Needham Virtual Healthcare Conference?

Christopher Posner, CEO of Cara Therapeutics, will participate in a fireside chat on April 11, 2022, at 1:30 p.m. ET.

How can I access the webcast of the Cara Therapeutics conference?

The webcast can be accessed under 'Events & Presentations' on Cara Therapeutics’ website.

What is KORSUVA and its significance for Cara Therapeutics?

KORSUVA™ (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in patients undergoing hemodialysis.

What additional developments is Cara Therapeutics pursuing?

Cara is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for treating pruritus in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.